Companies

AnaptysBio Announces $75 Million Stock Buyback Program

Published March 26, 2025

AnaptysBio (NASDAQ:ANAB) has recently revealed that its Board of Directors has approved a new stock repurchase program. This announcement was made on Monday, March 24th, as reported by RTT News. The biotechnology company intends to buy back a total of $75.00 million in shares. Under this authorization, AnaptysBio is permitted to repurchase up to 13.1% of its outstanding stock via open market purchases. Such buyback initiatives are often considered a positive sign, indicating that the company's management believes the stock is currently undervalued.

AnaptysBio Stock Performance

On the trading day following the announcement, shares of AnaptysBio saw an increase, climbing by $1.63 to reach a price of $18.71. Trading volume was notably high, with 2,201,872 shares changing hands, compared to the average volume of 546,082 shares. The company has a market capitalization of $573.78 million, a price-to-earnings ratio of -3.08, and a beta of 0.02. The fifty-day moving average for the stock stands at $16.80, while the two-hundred-day moving average is at $22.47. AnaptysBio's stock has a fifty-two week low of $12.21 and a fifty-two week high of $41.31.

In its most recent earnings report, released on February 27th, AnaptysBio reported a loss of ($0.72) earnings per share, outperforming analysts' expectations of a loss of ($1.61) by $0.89. The company also recorded a negative net margin of 289.75% and a return on equity of -287.94%. Revenue for the quarter amounted to $43.11 million, which is significantly higher than the analysts' estimate of $10.17 million. Analysts forecast that AnaptysBio will have a projected EPS of -6.08 for the current year.

Wall Street Analysts Forecast Growth

Several analysts have shared their perspectives on the company recently. Guggenheim reaffirmed a "buy" rating on AnaptysBio’s shares in a report issued on March 3rd. Meanwhile, Wedbush reiterated an "outperform" rating with a target price of $40.00 in a report published on February 12th. Wells Fargo & Company raised their price target from $40.00 to $51.00, providing the company with an "overweight" rating in a report on February 13th. Wolfe Research began coverage of AnaptysBio, assigning an “outperform” rating and setting a $25.00 target price in their report on February 4th. On the other hand, BTIG Research downgraded AnaptysBio from a "buy" rating to a "neutral" rating in a report on December 2nd. Presently, four analysts have issued hold ratings, six have given buy ratings, and one has classified it as a strong buy. According to MarketBeat, there is a consensus rating of "Moderate Buy" with an average target price of $35.11.

Insider Activity at AnaptysBio

In recent insider activity, Director Ecor1 Capital, LLC acquired 6,646 shares of AnaptysBio on January 2nd at an average price of $12.95 per share, totaling around $86,065.70. Following this purchase, the director's total ownership in the company has risen to 7,880,094 shares, now valued at approximately $102,047,217.30, reflecting a 0.08% increase in their stake. This transaction was disclosed in a legal filing with the SEC, emphasizing the ongoing insider interest in the company, with company insiders collectively owning 33.70% of the stock.

AnaptysBio Company Profile

AnaptysBio, Inc. is a clinical-stage biotechnology firm focused on developing therapeutic solutions in immunology. Its portfolio includes several products such as Rosnilimab, an IgG1 antibody targeting PD-1+ T cells that affect autoimmune and inflammatory diseases; ANB032, which is a non-depleting antibody aimed at the BTLA checkpoint receptor; ANB033, a novel anti-CD122 antagonist antibody; ANB101, targeted towards plasmacytoid dendritic cells (pDCs); and Imsidolimab, an interleukin-36 receptor-inhibiting antibody currently in Phase 3 development for treating generalized pustular psoriasis.

Should You Invest $1,000 in AnaptysBio Right Now?

Before making any investment decisions regarding AnaptysBio, it's essential to consider various options. Current ratings indicate a Moderate Buy consensus; however, analysts have also identified five other stocks they believe could perform better. It's beneficial to research extensively and weigh your options carefully before investing.